SEC Form 4 · accession 0001190725-17-000029
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP, Chief Science Officer
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 6:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 2,668 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Grant (Right to Buy)F2 | $5.40 | Jan 26, 2017 | A | 50,000 | A | — | Jan 25, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Includes 770 shares acquired under the ESPP on 11/30/16.
- F21/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.